A natural regulatory mutation in the proximal promoter elevates fetal globin expression by creating a de novo GATA1 site
- PMID: 30617196
- DOI: 10.1182/blood-2018-07-863951
A natural regulatory mutation in the proximal promoter elevates fetal globin expression by creating a de novo GATA1 site
Abstract
β-hemoglobinopathies, such as sickle cell disease and β-thalassemia, result from mutations in the adult β-globin gene. Reactivating the developmentally silenced fetal γ-globin gene elevates fetal hemoglobin levels and ameliorates symptoms of β-hemoglobinopathies. The continued expression of fetal γ-globin into adulthood occurs naturally in a genetic condition termed hereditary persistence of fetal hemoglobin (HPFH). Point mutations in the fetal γ-globin proximal promoter can cause HPFH. The -113A>G HPFH mutation falls within the -115 cluster of HPFH mutations, a binding site for the fetal globin repressor BCL11A. We demonstrate that the -113A>G HPFH mutation, unlike other mutations in the cluster, does not disrupt BCL11A binding but rather creates a de novo binding site for the transcriptional activator GATA1. Introduction of the -113A>G HPFH mutation into erythroid cells using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) system increases GATA1 binding and elevates fetal globin levels. These results reveal the mechanism by which the -113A>G HPFH mutation elevates fetal globin and demonstrate the sensitivity of the fetal globin promoter to point mutations that often disrupt repressor binding sites but here create a de novo site for an erythroid activator.
© 2019 by The American Society of Hematology.
Similar articles
-
Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.Elife. 2022 Feb 11;11:e65421. doi: 10.7554/eLife.65421. Elife. 2022. PMID: 35147495 Free PMC article.
-
Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.Nat Genet. 2018 Apr;50(4):498-503. doi: 10.1038/s41588-018-0085-0. Epub 2018 Apr 2. Nat Genet. 2018. PMID: 29610478
-
Activation of γ-globin gene expression by GATA1 and NF-Y in hereditary persistence of fetal hemoglobin.Nat Genet. 2021 Aug;53(8):1177-1186. doi: 10.1038/s41588-021-00904-0. Epub 2021 Aug 2. Nat Genet. 2021. PMID: 34341563 Free PMC article.
-
Molecular basis of hereditary persistence of fetal hemoglobin.Ann N Y Acad Sci. 1998 Jun 30;850:38-44. doi: 10.1111/j.1749-6632.1998.tb10460.x. Ann N Y Acad Sci. 1998. PMID: 9668525 Review.
-
DNA sequences regulating human globin gene transcription in nondeletional hereditary persistence of fetal hemoglobin.Hemoglobin. 1989;13(6):523-41. doi: 10.3109/03630268908993104. Hemoglobin. 1989. PMID: 2481658 Review.
Cited by
-
Improving adenine and dual base editors through introduction of TadA-8e and Rad51DBD.Nat Commun. 2023 Mar 3;14(1):1224. doi: 10.1038/s41467-023-36887-1. Nat Commun. 2023. PMID: 36869044 Free PMC article.
-
Structural basis for human ZBTB7A action at the fetal globin promoter.Cell Rep. 2021 Sep 28;36(13):109759. doi: 10.1016/j.celrep.2021.109759. Cell Rep. 2021. PMID: 34592153 Free PMC article.
-
Multimeric transcription factor BCL11A utilizes two zinc-finger tandem arrays to bind clustered short sequence motifs.Nat Commun. 2025 Apr 17;16(1):3672. doi: 10.1038/s41467-025-58998-7. Nat Commun. 2025. PMID: 40246927 Free PMC article.
-
Orphan Nuclear Receptors TR2 and TR4 in Erythropoiesis: From Mechanisms to Therapies.Biomolecules. 2025 May 31;15(6):798. doi: 10.3390/biom15060798. Biomolecules. 2025. PMID: 40563438 Free PMC article. Review.
-
Molecular Basis and Genetic Modifiers of Thalassemia.Hematol Oncol Clin North Am. 2023 Apr;37(2):273-299. doi: 10.1016/j.hoc.2022.12.001. Hematol Oncol Clin North Am. 2023. PMID: 36907603 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
